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B-cell chronic lymphocytic leukemia (B-
CLL) progression is frequently accompa-
nied by clinical lymphadenopathy, and
the CCL21 chemokine may play an impor-
tant role in this process. Indeed, CCR7
(the CCL21 receptor), as well as matrix
metalloproteinase-9 (MMP-9), are overex-
pressed in infiltrating B-CLL cells. We
have studied whether MMP-9 is regulated
by CCL21 and participates in CCL21-
dependent migration. CCL21 significantly
increased B-CLL MMP-9 production, mea-
sured by gelatin zymography. This was
inhibited by blocking extracellular signal-
regulated kinase-1/2 (ERK1/2) activity or
by cell transfection with CCR7-siRNA.
Accordingly, CCL21/CCR7 interaction ac-
tivated the ERK1/2/c-Fos pathway and
increased MMP-9 mRNA. CCL21-driven
B-CLL cell migration through Matrigel or
human umbilical vein endothelial cells
(HUVEC) was blocked by anti-CCR7 anti-
bodies, CCR7-siRNA transfection, or the
ERK1/2 inhibitor U0126, as well as by
anti-MMP-9 antibodies or tissue inhibitor
of metalloproteinase 1 (TIMP-1). These
results strongly suggest that MMP-9 is
involved in B-CLL nodal infiltration and
expand the roles of MMP-9 and CCR7 in
B-CLL progression. Both molecules could
thus constitute therapeutic targets for
this disease. (Blood. 2008;111:383-386)
© 2008 by The American Society of Hematology
Introduction
As B-cell chronic lymphocytic leukemia (B-CLL) progresses,
malignant cells extravasate and infiltrate lymphoid tissues.1,2
CCR7, the receptor for the CCL19 and CCL21 chemokines,3,4
plays an important role in B-CLL cell entry into lymph nodes, and
CCR7 overexpression correlates with the presence of lymphad-
enopathy.5,6 Another important contributor to B-CLL cell migration
may be matrix metalloproteinase-9 (MMP-9),7-9 which is produced
by B-CLL cells10-12 and overexpressed when these cells infiltrate
tissues with a diffuse pattern.11
We showed recently that MMP-9 is up-regulated by 41
integrin or CXCR4 (the CXCL12 chemokine receptor) engage-
ment12 and plays a crucial role in B-CLL cell migration through
basement membranes and human umbilical vein endothelial
cells (HUVEC).12 To further understand the role of MMP-9 in
B-CLL progression, we have now studied whether MMP-9 is
regulated by CCR7 ligation and/or involved in CCR7-dependent
migration.
Methods
Approval was obtained from the review boards of the Hospital Clı´nico
Universitario, Valencia, and the Hospital Universitario Puerta de Hierro,
Madrid, for these studies. Informed consent was obtained in accordance
with the Declaration of Helsinki.
Patients and cells
CD5 B-lymphocytes were purified from peripheral blood samples from
6 patients with B-CLL as reported previously.12 HUVECs were provided
by Dr M. L. Botella (Centro de Investigaciones Biolo´gicas, Madrid, Spain)
and cultured as described previously.12
Additional materials and methods can be found in Document S1
(available on the Blood website; see the Supplemental Materials link at the
top of the online article).
Results and discussion
To determine whether MMP-9 was regulated by CCR7 ligation,
B-CLL cells were incubated with or without CCL21; after
24 hours, the conditioned media were analyzed by gelatin zymogra-
phy. Figure 1A shows that CCL21 significantly increased (P  .01)
MMP-9 secretion compared with untreated cells. As previously
reported for B-CLL cells,11,12 MMP-9 was present as a 92-kDa
form. The CCL21 effect was completely blocked by inhibiting
CCR7 or ERK1/2 signaling with pertussis toxin (PT) or U0126,
respectively, while inhibiting phosphatidylinositol 3-kinase (PI3-
K), p38 mitogen-activated protein kinase (MAPK), protein kinase
C, or Src kinases, had no effect (Figure 1A). To study whether
CCL21 activated ERK1/2, cells were incubated with CCL21 and,
at various times, they were lysed and lysates analyzed by Western
blotting. CCL21 induced ERK1/2 phosphorylation, which peaked
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after 10 minutes of exposure (Figure 1B) and persisted for at least
24 hours (not shown). This effect was specifically inhibited by PT
and U0126 (Figure 1B). Further analysis of these samples revealed
that CCL21 also activated the ERK1/2 effector c-fos13 (Figure 1C),
suggesting that CCL21/CCR7 may regulate MMP-9 at various
levels including gene transcription. Indeed, CCL21 significantly
increased MMP-9 mRNA levels measured after 6 to 16 hours of
exposure, then declining after 24 hours (Figure S1).
To further establish that the CCL21/CCR7 interaction was
responsible for MMP-9 up-regulation, we studied the effect of
CCL21 on siRNA transfected cells. Transfection with control
siRNA did not affect CCR7 surface expression (Figure 1D) or
MMP-9 induction by CCL21 (Figure 1E), indicating that MMP-9
production was not impaired by the procedure. However, CCR7
gene silencing significantly inhibited CCR7 expression (Figure
1D), and CCL21-induced MMP-9 up-regulation (Figure 1E),
confirming the specificity of the effect. Moreover, CXCL12,
another chemokine that up-regulates MMP-9 upon binding to
CXCR4,12 enhanced MMP-9 levels on CCR7 siRNA-cells (Figure
1E), indicating that both axes, CCL21/CCR7 and CXCL12/
CXCR4, functioned independently from each other. Indeed, simul-
taneous treatment with CCL21 and CXCL12 did not have an
additive effect on MMP-9 production (Figure 1E). This probably
reflects the physiologic situation in which the 2 chemokines are
associated with different tissues4 yet may provide a continuous
stimulus for MMP-9 production.
We next studied whether MMP-9 was involved in CCL21-
induced cell migration. B-CLL cells migrated through Matrigel
or HUVEC in response to CCL21, and this was completely
inhibited by PT, anti-CCR7 antibodies (Abs), or CCR7 siRNA
transfection (Figure 2A,B). U0126 also blocked cell migration
in both systems, whereas PI3-K or p38 MAPK inhibitors had no
significant effect. It is noteworthy that anti-MMP-9 Abs or the
MMP-9–specific inhibitor known as tissue inhibitor of metallo-
proteinase 1 (TIMP-1), but not control anti-MT1-MMP Abs,
inhibited cell migration (Figure 2A,B). To determine whether
MMP-9 enzymatic activity was involved in this effect, we
incubated the conditioned media of untreated or CCL21-treated
B-CLL cells with FITC-gelatin and measured the fluorescence
after 24 hours. Incubation with the conditioned media of
untreated cells had a minor effect, but the conditioned media of
CCL21-treated cells significantly decreased the fluorescence
(Figure 2C). This was reversed by anti-MMP-9 Abs or TIMP-1,
whereas these compounds had no effect in the absence of
conditioned media (Figure 2C). These results indicated that
secreted MMP-9 had catalytic activity, that this activity was
clearly increased upon CCL21 treatment (which enhances
MMP-9 production), and that its role in cell migration probably
Figure 1. CCL21 up-regulates MMP-9 via ERK1/2
signaling. (A) B-CLL cells were treated or not with
1000 ng/mL CCL21 in the presence or absence of the
indicated inhibitors (PT, 200 ng/mL; Wortmannin (Wmn),
30 nmol/L; the rest, 5 mol/L). After 24 hours, the
conditioned media was analyzed by gelatin zymography.
(B) Western blots of lysates of B-CLL cells treated or not
(10 minutes) with CCL21, and with or without the indi-
cated inhibitors. (C) Reverse transcription-polymerase
chain reaction analysis of c-fos in the same samples
shown in (B). Vertical lines in (A) and (C) have been
inserted to indicate a repositioned gel lane. (D) Flow
cytometric analysis of CCR7 expression in untransfected
(continuous lines), control siRNA- (dotted lines) or CCR7
siRNA-transfected (shaded areas) cells. (E) Gelatin
zymographic analysis of the conditioned media of untrans-
fected or siRNA-transfected cells treated or not with
CXCL12 or CCL21 for 24 hours. Error bars represent
SD. *P  .05; **P  .01.
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involves the degradation of the matrix and/or basement mem-
brane. Despite this functional assay, the mature 85-kDa MMP-9
form was not detected in the B-CLL conditioned media. Similar
observations have been reported previously for other cell
types.14 Although the reason for this remains unclear, one
possibility is that mature MMP-9 is produced at levels that are
undetectable yet sufficient for focalized activity. MMP-9 activa-
tion most likely occurs at the pericellular space, where several
proteases, including plasmin, may be present. MMP-9 could
also be activated by nonproteolytic mechanisms (conforma-
tional changes, oxidative modifications)14 thus resulting in an
active 92-kDa enzyme.
Our results therefore establish a novel role for the CCL21/
CCR7 axis as a MMP-9 regulator and clearly show that MMP-9 is
an important mediator in CCL21-driven cell migration. CCL21 is
expressed in high endothelial venules, a major route for lympho-
cyte homing to lymphoid tissues,15-17 and lack of CCR7 impairs
B-cell entry into lymph nodes.18 Besides its role in B-CLL nodal
infiltration, CCR7 may also induce B-CLL cell survival,19 thus
contributing in various ways to B-CLL progression. Our present
findings expand the CCR7 roles in B-CLL and strongly suggest that
MMP-9 is involved in B-CLL lymph node infiltration. MMP-9
and/or CCR7 could therefore constitute targets for treatment of
this malignancy.
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